Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma

Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma

(2013) T M Meniawy et al.   BRITISH JOURNAL OF CANCER

Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma

(2012) Harvey I. Pass et al.   NEW ENGLAND JOURNAL OF MEDICINE

A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit

(2012) Amanda Segal et al.   PATHOLOGY

Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma—Which is best?

(2011) Jenette Creaney et al.   LUNG CANCER

Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma

(2010) J. Creaney et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy

(2010) S. C. H. Kao et al.   CLINICAL CANCER RESEARCH

EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells

(2009) Peter Camaj et al.   BIOLOGICAL CHEMISTRY

Fibulin-3 Is Uniquely Upregulated in Malignant Gliomas and Promotes Tumor Cell Motility and Invasion

(2009) B. Hu et al.   MOLECULAR CANCER RESEARCH

Problems in mesothelioma diagnosis

(2008) Bruce Addis et al.   HISTOPATHOLOGY